Back to News
Market Impact: 0.4
Contineum's Phase 2 MOONLIGHT-1 Trial Misses Primary Endpoint In MDD; Stock Down
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Contineum Therapeutics said its Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 monotherapy in adults with major depressive disorder failed to achieve its primary efficacy endpoint. The result is a material clinical-development setback for the asset and could pressure Contineum shares and expectations for the program's future development.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.65
Ticker Sentiment
CTNM-0.85
More News
- Grab aims for 'next level' in financial services with purchase of buy-now pay-later platform Atome
- China's AI leaders keep quiet despite U.S. 'publicity' on tech risks
- Exclusive-Malaysia talks to rival airlines as it monitors AirAsia’s financial health, sources say
- Is Amazon Stock a Buy After Its Best Quarter in Years?
- Australia’s Reliance Worldwide agrees to Brookfield’s $2.9 billion buyout bid
- Trip.com swings to Q2 loss after $763 million antitrust penalty
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Selecting an AI Research Platform for Institutional Investors
- Weekly Update: New Reporting Features and More Sources for Document Search